Low Escitalopram Concentrations in Patients with Depression predict Treatment Failure: A Naturalistic Retrospective Study.

IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pharmacopsychiatry Pub Date : 2023-03-01 DOI:10.1055/a-2039-2829
Xenia M Hart, Friederike Amann, Jonas Brand, Luzie Eichentopf, Gerhard Gründer
{"title":"Low Escitalopram Concentrations in Patients with Depression predict Treatment Failure: A Naturalistic Retrospective Study.","authors":"Xenia M Hart,&nbsp;Friederike Amann,&nbsp;Jonas Brand,&nbsp;Luzie Eichentopf,&nbsp;Gerhard Gründer","doi":"10.1055/a-2039-2829","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cross sectional therapeutic drug monitoring (TDM) data mining introduces new opportunities for the investigation of medication treatment effects to find optimal therapeutic windows. Medication discontinuation has been proven useful as an objective surrogate marker to assess treatment failure. This study aimed to investigate the treatment effects of escitalopram and pharmacokinetic influences on blood levels using retrospectively assessed data from a TDM database.</p><p><strong>Methods: </strong>Data was collected from 134 patients longitudinally treated with escitalopram for whom TDM was requested to guide drug therapy. Escitalopram metabolism was estimated by the log-transformed dose-corrected concentrations and compared within subpopulations differing in age, gender, renal function, smoking status, body mass index, and comedication.</p><p><strong>Results: </strong>Patients with a depressive episode who were treated with escitalopram and discontinued the treatment within the hospital stay showed lower serum concentrations compared to patients who continued escitalopram treatment with a concentration of 15 ng/mL separating both groups. Variability was high between individuals and factors influencing blood levels, including dose, sex, and age. Comedication that inhibits cytochrome P450 (CYP) 2C19 isoenzymes were further found to influence escitalopram pharmacokinetics independent of dose, age or sex.</p><p><strong>Discussion: </strong>Medication switch is a valuable objective surrogate marker to assess treatment effects under real-world conditions. Of note, treatment discontinuation is not always a cause of insufficient response but may also be related to other factors such as medication side effects. TDM might not only be useful in addressing these issues but titrating drug concentrations into the currently recommended reference range for escitalopram will also increase response in non-responders and avoid treatment failure in underdosed patients.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":"56 2","pages":"73-80"},"PeriodicalIF":3.6000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/57/10-1055-a-2039-2829.PMC10030201.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacopsychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2039-2829","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Cross sectional therapeutic drug monitoring (TDM) data mining introduces new opportunities for the investigation of medication treatment effects to find optimal therapeutic windows. Medication discontinuation has been proven useful as an objective surrogate marker to assess treatment failure. This study aimed to investigate the treatment effects of escitalopram and pharmacokinetic influences on blood levels using retrospectively assessed data from a TDM database.

Methods: Data was collected from 134 patients longitudinally treated with escitalopram for whom TDM was requested to guide drug therapy. Escitalopram metabolism was estimated by the log-transformed dose-corrected concentrations and compared within subpopulations differing in age, gender, renal function, smoking status, body mass index, and comedication.

Results: Patients with a depressive episode who were treated with escitalopram and discontinued the treatment within the hospital stay showed lower serum concentrations compared to patients who continued escitalopram treatment with a concentration of 15 ng/mL separating both groups. Variability was high between individuals and factors influencing blood levels, including dose, sex, and age. Comedication that inhibits cytochrome P450 (CYP) 2C19 isoenzymes were further found to influence escitalopram pharmacokinetics independent of dose, age or sex.

Discussion: Medication switch is a valuable objective surrogate marker to assess treatment effects under real-world conditions. Of note, treatment discontinuation is not always a cause of insufficient response but may also be related to other factors such as medication side effects. TDM might not only be useful in addressing these issues but titrating drug concentrations into the currently recommended reference range for escitalopram will also increase response in non-responders and avoid treatment failure in underdosed patients.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
低艾司西酞普兰浓度抑郁症患者预测治疗失败:一项自然的回顾性研究。
简介:横断面治疗药物监测(TDM)数据挖掘为研究药物治疗效果,寻找最佳治疗窗口提供了新的机会。停药已被证明是评估治疗失败的客观替代指标。本研究旨在利用TDM数据库的回顾性评估数据,探讨艾司西酞普兰的治疗效果和药代动力学对血药浓度的影响。方法:收集134例经艾司西酞普兰治疗并以TDM指导药物治疗的患者资料。通过对数转换剂量校正浓度估计艾司西酞普兰的代谢,并在不同年龄、性别、肾功能、吸烟状况、体重指数和用药的亚群中进行比较。结果:接受艾司西酞普兰治疗并在住院期间停止治疗的抑郁发作患者的血清浓度低于继续接受艾司西酞普兰治疗的患者,两组患者的浓度为15 ng/mL。个体和影响血药浓度的因素(包括剂量、性别和年龄)之间的差异很大。进一步发现抑制细胞色素P450 (CYP) 2C19同工酶的药物影响艾司西酞普兰的药代动力学与剂量、年龄或性别无关。讨论:药物转换是评估现实条件下治疗效果的一个有价值的客观替代指标。值得注意的是,停止治疗并不总是反应不足的原因,也可能与药物副作用等其他因素有关。TDM可能不仅有助于解决这些问题,而且将药物浓度滴定到目前推荐的依西酞普兰参考范围也将增加无反应患者的反应,并避免剂量不足患者的治疗失败。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmacopsychiatry
Pharmacopsychiatry 医学-精神病学
CiteScore
7.10
自引率
9.30%
发文量
54
审稿时长
6-12 weeks
期刊介绍: Covering advances in the fi eld of psychotropic drugs, Pharmaco psychiatry provides psychiatrists, neuroscientists and clinicians with key clinical insights and describes new avenues of research and treatment. The pharmacological and neurobiological bases of psychiatric disorders are discussed by presenting clinical and experimental research.
期刊最新文献
Impact of Parkinson Medication on Neuropsychiatric and Neurocognitive Symptoms in Patients with Advanced Parkinson Disease Prior to Deep Brain Stimulation. Impact of Antipsychotic Medications on Weight Gain and Eating Disorder-Related Psychopathology in Adult Inpatients with Anorexia Nervosa. Activation of Hippocampal Neuronal NADPH Oxidase NOX2 Promotes Depressive-Like Behaviour and Cognition Deficits in Chronic Restraint Stress Mouse Model. Early Treatment-Resistance in First Episode Psychosis. ABC Family Gene Polymorphisms and Cognitive Functions Interact to Influence Antidepressant Efficacy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1